Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis-Reference-Cited by-同舟云学术

Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis

Published:2019-12-20 Issue:1 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

van Wijk Floor¹²,Waterval Jérôme³⁴,van Aerde Koen¹,Henriet Stefanie S. V.¹,Meijer F. J. Anton⁵,Borra Lennaert C.⁶,Aarnoutse Rob E.⁶,van Ingen Jakko⁷^ORCID

Affiliation:

1. Department of Pediatrics, Amalia’s Children Hospital, Radboud University Medical Center, Nijmegen, the Netherlands

2. University Hospital Brussels, Department of Pediatrics, Brussels, Belgium

3. Department of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, the Netherlands

4. Department of Otorhinolaryngology, Maastricht University Medical Center, Maastricht, the Netherlands

5. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands

6. Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands

7. Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands

Abstract

Mycobacterium abscessus is an extensively drug-resistant opportunistic pathogen that can cause chronic otomastoiditis. There are no evidence-based treatment regimens for this severe infection. We treated four children with M. abscessus otomastoiditis with a structured regimen of topical imipenem and tigecycline, intravenous imipenem and tigecycline, and oral clofazimine and azithromycin and adjunctive surgery. This structured approach led to cure, with 1 year of follow-up after treatment.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01203-19

Reference10 articles.

1. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed., M24-A2. CLSI, Wayne, PA.

2. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases

3. Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions;Bigley FP;Am J Hosp Pharm,1986

4. A Novel Formulation of Tigecycline Has Enhanced Stability and Sustained Antibacterial and Antileukemic Activity

5. Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world safety profile of tetracyclines in children younger than 8 years old: an analysis of FAERS database and review of case report;Expert Opinion on Drug Safety;2024-05-28

2. Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine;Infection;2024-02-08

3. Quarterly Round-up of Notable Articles (December 2023- February 2024);Journal of Clinical Infectious Disease Society;2024-01

4. Case Commentary: Another prong of attack? Topical antibiotic instillation with negative pressure wound therapy for nontuberculous mycobacterial skin and soft tissue infections;Antimicrobial Agents and Chemotherapy;2023-12-14

5. Successful addition of topical antibiotic treatment after surgery in treatment-refractory nontuberculous mycobacterial skin and soft tissue infections;Antimicrobial Agents and Chemotherapy;2023-12-14